Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Isatuximab · Sarclisa, Sarclisa Escena

Monoclonal antibody · Cytotoxic, directed at CD38 · developed by Sanofi Aventis Us

Approved FDA, Mar 2020
SNY Developer
1 Registered trials

What is Isatuximab?

Isatuximab is an IgG1-derived monoclonal antibody that binds CD38 on hematopoietic and tumor cells, including multiple myeloma cells. It induces tumor cell apoptosis and immune effector killing through ADCC, ADCP and complement-dependent cytotoxicity, and inhibits CD38's ADP-ribosyl cyclase activity. It is studied in monoclonal gammopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Sarclisa, Sarclisa Escena, SAR-650984
Drug type
Monoclonal antibody
Targets
CD38
Mechanism
Cytotoxic, directed at CD38
Pathways
apoptosis, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, complement-dependent cytotoxicity, NK cell activation
Therapy area
Hematology, Immunology
Developer
Sanofi Aventis Us (SNY)
FDA status
Approved as Sarclisa, Sarclisa Escena (March 2, 2020), BLA761113 · FDA label
UNII
R30772KCU0

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04643002 Phase 1/2 Plasma Cell Myeloma Refractory Recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Monoclonal Gammopathy

Other drugs acting on CD38

More from Sanofi Aventis Us

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Isatuximab

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.